Sequential cisplatin-gemcitabine-docetaxel vs docetaxel-gemcitabine in the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC):: Interim results of an ongoing phase II trial.

被引：0
|
作者：
Binder, D
Beinert, T
Schweisfurth, H
Grah, C
Temmesfeld-Wollbrock, B
Müller-Hagen, G
Schäper, C
Schürmann, D
Suttorp, N
机构：
[1] Med Klin Infektiolog, Berlin, Germany
[2] Klin Warternberg, Wartenberg, Germany
[3] Med Klin, Cottbus, Germany
[4] Med Klin Kardiol Pneumol, Berlin, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2004年 / 22卷 / 14期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7113
引用
收藏
页码：644S / 644S
页数：1
相关论文
共 50 条
  • [1] Docetaxel-gemcitabine versus cisplatin-gemcitabine plus sequential docetaxel in the first-line treatment of metastatic non-small cell lung cancer (NSCLC): interim results of a randomized Phase II trial
    Binder, Daniel
    Beinert, Thomas
    Schweisfurth, Hans
    Grah, Christian
    Temmestfeld-Wollbrueck, Bettina
    Schaeper, Christoph
    Mueller-Hagen, Gerit
    Schuermann, Dirk
    Suttorp, Norbert
    [J]. ANNALS OF ONCOLOGY, 2004, 15 : 178 - 178
  • [2] Docetaxel/gemcitabine vs. cisplatin/gemcitabine followed by docetaxel in the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC):: Results of a randomised phase II trial
    Binder, D
    Schweisfurth, H
    Grah, C
    Schäper, C
    Temmesfeld-Wollbrück, B
    Siebert, G
    Suttorp, N
    Beinert, T
    [J]. LUNG CANCER, 2005, 49 : S237 - S237
  • [3] Docetaxel/gemcitabine or cisplatin/gemcitabine followed by docetaxel in the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC): results of a multicentre randomized phase II trial
    D. Binder
    H. Schweisfurth
    C. Grah
    C. Schäper
    B. Temmesfeld-Wollbrück
    G. Siebert
    N. Suttorp
    T. Beinert
    [J]. Cancer Chemotherapy and Pharmacology, 2007, 60 : 143 - 150
  • [4] Docetaxel/gemcitabine or cisplatin/gemcitabine followed by docetaxel in the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC):: results of a multicentre randomized phase II trial
    Binder, D.
    Schweisfurth, H.
    Grah, C.
    Schaeper, C.
    Temmesfeld-Wollbrueck, B.
    Siebert, G.
    Suttorp, N.
    Beinert, T.
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2007, 60 (01) : 143 - 150
  • [5] Docetaxel/gemcitabine vs. a sequential protocol comprising cisplatin/gemcitabine/docetaxel in the first-line treatment of patients with stage IV non-small cell lung cancer (NSCLC):: results of a randomised phase II trial
    Binder, D.
    Schweisfurth, H.
    Grah, C.
    Schaper, C.
    Temmesfeld-Wollbruck, B.
    Siebert, G.
    Suttorp, N.
    Beinert, T.
    [J]. EJC SUPPLEMENTS, 2005, 3 (02): : 326 - 326
  • [6] Sequential carboplatin-gemcitabine (CG) and docetaxel (D) in the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC): A phase II trial.
    Murad, AM
    Guimaraes, RC
    Scalabrini-Neto, AO
    Papa, AM
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 708S - 708S
  • [7] Comparison of docetaxel/cisplatin to docetaxel/gemcitabine as first-line treatment of advanced non-small cell lung cancer: early results of a randomized trial
    Georgoulias, V
    Samonis, G
    Papadakis, E
    Alexopoulos, A
    Tsiafaki, X
    Rapti, A
    Veslemes, M
    Grigoratou, T
    Palamidas, P
    Kourossis, C
    Mavroudis, D
    Kakolyris, S
    Giannakakis, T
    Vlachonikolis, J
    [J]. LUNG CANCER, 2001, 34 : S47 - S51
  • [8] Weekly docetaxel-gemcitabine as first-line treatment in advanced non-small cell lung cancer: Preliminary results of a phase II study.
    Kalmadi, SR
    Mekhail, T
    Adelstein, D
    Giannini, C
    Peereboom, D
    Olencki, T
    Davis, M
    Bukowski, R
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 675S - 675S
  • [9] A phase II study of sequential docetaxel and gemcitabine followed by docetaxel and carboplatin as first-line therapy for non-small cell lung cancer
    Eleni M. Karapanagiotou
    Adrianni Charpidou
    Ifigenia Tzannou
    Kalliopi Dilana
    Elias Kotteas
    Ioannis Tourkantonis
    Epaminondas Kosmas
    Aspasia Provata
    Kostas Syrigos
    [J]. Medical Oncology, 2008, 25 : 303 - 308
  • [10] A phase II study of sequential docetaxel and gemcitabine followed by docetaxel and carboplatin as first-line therapy for non-small cell lung cancer
    Karapanagiotou, Eleni M.
    Charpidou, Adrianni
    Tzannou, Ifigenia
    Dilana, Kalliopi
    Kotteas, Elias
    Tourkantonis, Ioannis
    Kosmas, Epaminondas
    Provata, Aspasia
    Syrigos, Kostas
    [J]. MEDICAL ONCOLOGY, 2008, 25 (03) : 303 - 308
12345